SFI
BLCM

Susquehanna Fundamental Investments’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Susquehanna Fundamental Investments’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-13,300
Closed -$50K – 1822
2021
Q1 		$50K Buy
+13,300
New +$57.8K ﹤0.01% 1497

Other funds holding BLCM

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return

Susquehanna Fundamental Investments's BLCM Position: Q2 2021 in Review

Susquehanna Fundamental Investments sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2021, closing a stake of 13,300 shares — an estimated $50K sold.

Susquehanna Fundamental Investments first reported a position in BLCM in Q1 2021 and held it in 1 quarter. The position peaked at $50K in Q1 2021. 30 funds tracked by Wall St. Rank hold BLCM as of Q2 2021.

  • Susquehanna Fundamental Investments reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 13,300 Bellicum Pharmaceuticals, Inc. shares in Q2 2021, an estimated $50K.
  • Susquehanna Fundamental Investments first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2021 and held it in 1 quarter.
  • Susquehanna Fundamental Investments's Bellicum Pharmaceuticals, Inc. position peaked at $50K in Q1 2021.
  • 30 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2021, filed 11 Aug 2021.